Our products are co-designed by patients, clinicians, engineers, & researchers. They are only available via clinicians as part of a package of care

CareLoop platform

The CareLoop platform provides healthcare workers with real-time symptom insights to inform decision making on treatment and management options. Prediction using proprietary AI within the platform identifies potential markers of escalation for early intervention and prevention.

An extensive global research study commences in 2022 to further the CareLoop predictive AI with the ultimate aim of preventing relapse in psychosis and schizophrenia.

CareLoop app

The CareLoop app sits on a patient’s smartphone linking back to a secure CareLoop platform server. We have created a dynamic framework that supports multi-content delivery, ensuring a patient’s experience is based on their clinicial need.

The app is currently available and has been robustly tested for use by people with psychosis/schizophrenia, and to support perinatal mental health in new parents.

Want to know more?

CareLoop leads to significantly faster improvement in psychotic symptoms compared to standard care

Since 2010 we have worked with patients and clinicians to demonstrate the value of digital technology in the treatment and management of psychosis/schizophrenia. Using proprietary, clinically validated assessment questionnaires, CareLoop collects real-time symptom data for use by patients and healthcare workers. Insights inform patient self-management and healthcare decision making, including safer and more effective medication management.

Predictive technology identifies escalation and risk of relapse for healthcare worker or peer intervention. Cognitive behavioural therapy (CBT) is shown to be helpful for people who have experienced a first episode of psychosis and is recommended in clinical treatment guidelines for psychosis/schizophrenia in many countries around the world. Through clinical trials proactive CBT strategies within the CareLoop app provide clinical benefit to support recovery.
80% of people who experience a first episode of psychosis will relapse within five years

CareLoop is proven to support perinatal mental health by screening for postnatal depression as effectively as in-person tools

CareLoop helps overcome many of the barriers of conventional health visitor delivered screening, such as limited staff time, parental unwillingness to disclose difficulties to a professional, lack of partner/father screening, and language barriers.

The lifelong costs and consequences of untreated postnatal depression (PND) are high due to impact on infants as well as parents, yet it is been shown that more than half of cases go undetected or untreated.

Using the Edinburgh Postnatal Depression Scale (EPDS), CareLoop collects daily data on parent wellbeing, helping to identifying those at risk of postnatal depression for timely intervention by a health visitor.

17% of mums experience major depression the year after birth, although less common partners & fathers also experience postnatal depression

Product pipeline

CareLoop is accredited by the world’s leading, independent health and care app evaluation organisation, ORCHA. We are currently processing CE Mark Medical Device accreditation.

Programme Research name Description Research & development Clinical evaulation Regulation/compliance Roll out
CLH-001 CareLoop platform AI 2010     checked
CLH-002 ClinTouch Real-time symptom monitoring 2010   ORCHA rating 88%
CE Mark in progress
CLH-003 Empower Predictive relapse monitoring 2016   ORCHA rating 88%*
CE Mark in progress
CLH-004 Actissist CBT content augmentation 2015   ORCHA rating 91% checked
CLH-005 Dawn-P Postnatal depression screening 2021   checked  
CLH-006 DTx Integrated CBT & early warning algorithm 2022      
CLH-007 Connect AI predictive relapse technology 2022 checked